Canada has established itself as a Western hub for cost-effective pharma manufacturing according to a report comparing international business costs.
KPMG's Competitive Alternatives 2006 report compared business costs in nine industrialised nations across North America, Europe and the Asia Pacific, in order to provide valuable information for any company seeking cost advantages in locating their international business operations.
While Singapore was hailed as the number one industrialised location to cost-effectively manufacture pharmaceuticals, Canada was the leading country of the West, hosting four out of the five top locations pinpointed in the survey.
Moncton and Sherbrooke, both in Quebec, St. John's in Newfoundland and Halifax in Nova Scotia were all leading the charge for Canada.
Countries following behind Canada in positions three and four were France, with one city featuring in the top ten, and the Netherlands, trailed in fifth and sixth place by Italy and the UK.
The US only managed to make it to number seven in the scale of cost-effectiveness, with its top city, Dothan, Alabama, ranking twelth.
Japan and Germany were listed among the most expensive locations, coming in at positions eight and nine.
KPMG said that the rankings were calculated after taking into account the combined impact of 27 location-sensitive cost components, including salaries, transportation, utilities and taxes, over a ten-year period.